Oncolytics Biotech® Reports First Quarter Financial Results and Highlights Clinical Momentum
Pelareorep featured in Key Opinion Leader event on oncolytic immunotherapies in breast and pancreatic cancers
Poster on pelareorep's stimulation of adaptive and innate immunity to be shared at ASCO Annual Meeting
Conference call and webcast today at 4:30 p.m. ET to discuss Q1 results and clinical outlook
SAN DIEGO, Calif. and CALGARY, AB, May 14, 2025 /CNW/ -- Oncolytics Biotech ® Inc. (NASDAQ: ONCY) (TSX: ONC), a leading clinical-stage company specializing in immunotherapy for oncology, today reported on highlights and financial results for the first quarter of 2025. All dollar amounts are expressed in Canadian currency unless otherwise noted.
"Pelareorep continues to build clinical momentum, delivering encouraging results in challenging cancer types and has the potential to extend and improve the lives of patients," said Wayne Pisano, Chair of Oncolytics' Board of Directors and Interim CEO. "We remain focused on optimizing the development pathway for pelareorep. Importantly, pelareorep has demonstrated a meaningful clinical benefit in two randomized phase 2 breast cancer studies, in multiple pancreatic cancer studies, and now in anal cancer as well. This versatility and broad potential applicability are achieved via intravenous administration and the ability to combine with chemotherapies and checkpoint inhibitors while maintaining a favorable safety profile."
First Quarter and Subsequent Highlights
Upcoming poster presentation at this year's ASCO Annual Meeting. The title of the poster that will be presented at the conference is: Role of pelareorep in activating anti-tumor immunity in PDAC and will share data exhibiting pelareorep's ability to elicit innate as well as adaptive immune responses in an extremely challenging indication (link to the PR).
Two posters were presented at the 2025 ASCO Gastrointestinal Cancers Symposium, one in anal carcinoma and one in pancreatic ductal adenocarcinoma (link to the PR).
Updated interim efficacy results from GOBLET Cohort 4 showed pelareorep combined with atezolizumab demonstrated an objective response rate of 33% in twelve evaluable patients with second-line or later unresectable squamous cell anal carcinoma, including a complete and durable response lasting over 15 months - an encouraging signal in this difficult-to-treat cancer (link to the poster). The response rates recorded continue to exceed historical control trials, and enrollment has been expanded to confirm the promising efficacy signal and potentially pave the way for a registration-enabling study.
In GOBLET Cohort 5, patients with newly diagnosed metastatic pancreatic ductal adenocarcinoma (PDAC) were treated with pelareorep + modified FOLFIRINOX +/- atezolizumab. As required by the protocol, six patients completed the safety run-in and follow-up period. A review of safety data was completed by the independent Data Safety Monitoring Board (DSMB) and the Paul Ehrlich Institute (PEI), Germany's medical regulatory body, and both groups recommended study continuation (link to the poster). This cohort is being funded by the Pancreatic Cancer Action Network (PanCAN) and, depending on the results, could expand the potential of pelareorep combination therapy in this indication.
Key opinion leader event highlights oncolytic immunotherapies in breast and pancreatic cancers. In a webinar hosted by H.C. Wainwright, key opinion leaders Professor Martine Piccart, a co-founder of the Breast International Group (BIG) and member of the Belgian Royal Academy of Medicine, and Alexander Eggermont, Professor of Immunotherapy at Utrecht University Medical and Board Member of the Comprehensive Cancer Center Munich of the Technical University Munich and the Ludwig Maximilians University, discussed the need for new treatment options as well as pelareorep's ability to activate the immune system to identify and attack tumors (link to the PR).
Share purchase agreement with institutional investor Alumni Capital LP supports ongoing clinical development. Oncolytics entered into a US$20 million share purchase agreement (SPA) providing a flexible source of funding, enabling the Company to progress towards key clinical milestones. Under the terms of the SPA, the Company, at its sole discretion, controls the timing and amount of all sales of common stock and does not entail any warrant coverage or other classes of shares (link to the PR).
Financial Highlights
As of March 31, 2025, the Company reported $15.3 million in cash and cash equivalents, projecting a cash runway through key milestones and through the third quarter of 2025.
The net loss for the first quarter of 2025 was $6.7 million, compared to a net loss of $6.9 million for the first quarter of 2024. The basic and diluted loss per share was $0.08 in the first quarter of 2025, compared to a basic and diluted loss per share of $0.09 in the first quarter of 2024.
Research and development expenses for the first quarter of 2025 were $4.1 million, compared to $5.7 million for the first quarter of 2024. The decrease was primarily attributable to lower manufacturing and clinical trial expenses. This decrease was partially offset by higher personnel-related and share-based compensation expenses associated with CEO transition activities.
General and administrative expenses for the first quarter of 2025 were $3.0 million, consistent with $3.0 million for the first quarter of 2024.
Net cash used in operating activities for the three months ended March 31, 2025, was $6.5 million, compared to $7.5 million for the three months ended March 31, 2024. The decrease reflected lower net operating activities, partly offset by higher non-cash working capital changes.
Anticipated Milestones
Q2 2025: Pancreatic cancer translational data from Cohort 1 of the GOBLET study evaluating pelareorep, gemcitabine, nab-paclitaxel, and atezolizumab
H1 2026: Initial efficacy results from Cohort 5 of the GOBLET study investigating pelareorep combined with modified FOLFIRINOX with or without atezolizumab in newly diagnosed metastatic pancreatic cancer
Webcast and Conference Call
Management will host a conference call for analysts and investors at 4:30 p.m. ET today, May 14, 2025. To access the call, please dial (888) 510-2154 (North America) or (437) 900-0527 (International), and if needed, provide Conference ID: 28038. To join the conference call without operator assistance, please click here. A live webcast of the call will also be available by clicking here or on the Investor Relations page of Oncolytics' website, available by clicking here, and will be archived for three months. A dial-in replay will be available for one week and can be accessed by dialing (888) 660-6345 (North America) or (289) 819-1450 (International) and using replay code: 28038#.
ONCOLYTICS BIOTECH INC.
CONDENSED INTERIM CONSOLIDATED STATEMENTS OF FINANCIAL POSITION
(unaudited)
(in thousands of Canadian dollars, except share amounts)
As at
March 31,
2025
December 31,
2024
Assets
Current assets
Cash and cash equivalents
$ 15,303
$ 15,942
Other receivables
89
68
Prepaid expenses
1,875
1,885
Warrant derivative
1,220
980
Total current assets
18,487
18,875
Property and equipment
386
411
Right-of-use assets
829
901
Total assets
$ 19,702
$ 20,187
Liabilities and Shareholders' Equity
Current liabilities
Accounts payable and accrued liabilities
$ 4,948
$ 4,792
Other liabilities
530
1,618
Lease liabilities
290
277
Total current liabilities
5,768
6,687
Contract liability
6,730
6,730
Lease liabilities
710
787
Total liabilities
13,208
14,204
Commitments
Shareholders' equity
Share capital
Authorized: unlimited
Issued: March 31, 2025 – 86,421,592
December 31, 2024 – 80,020,131
445,533
438,193
Contributed surplus
44,403
44,542
Accumulated other comprehensive income
958
961
Accumulated deficit
(484,400)
(477,713)
Total shareholders' equity
6,494
5,983
Total liabilities and shareholders' equity
$ 19,702
$ 20,187
ONCOLYTICS BIOTECH INC.
CONDENSED INTERIM CONSOLIDATED STATEMENTS OF LOSS AND COMPREHENSIVE LOSS
(unaudited)
(in thousands of Canadian dollars, except share amounts)
Three Months Ended March 31,
2025
2024
Expenses
Research and development
$ 4,083
$ 5,743
General and administrative
2,916
2,983
Loss before the following
(6,999)
(8,726)
Change in fair value of warrant derivative
240
869
Foreign exchange (loss) gain
(51)
517
Interest income, net
123
446
Net loss
(6,687)
(6,894)
Other comprehensive (loss) income items that may be reclassified to net loss
Translation adjustment
(3)
126
Comprehensive loss
$ (6,690)
$ (6,768)
Basic and diluted loss per common share
$ (0.08)
$ (0.09)
Weighted average number of shares (basic and diluted)
84,631,445
75,244,637
ONCOLYTICS BIOTECH INC.
CONDENSED INTERIM CONSOLIDATED STATEMENTS OF CHANGES IN EQUITY
(unaudited)
(in thousands of Canadian dollars)
Share Capital
Contributed
Surplus
Accumulated
Other
Comprehensive
Income
Accumulated
Deficit
Total
As at December 31, 2023
$ 430,906
$ 42,116
$ 544
$ (446,003)
$ 27,563
Net loss and other comprehensive income
—
—
126
(6,894)
(6,768)
Issued pursuant to incentive share award plan
3
(3)
—
—
—
Issued pursuant to "At the Market" Agreement
1,669
—
—
—
1,669
Share issue costs
(71)
—
—
—
(71)
Share-based compensation expense
—
576
—
—
576
As at March 31, 2024
$ 432,507
$ 42,689
$ 670
$ (452,897)
$ 22,969
As at December 31, 2024
$ 438,193
$ 44,542
$ 961
$ (477,713)
$ 5,983
Net loss and other comprehensive loss
—
—
(3)
(6,687)
(6,690)
Issued pursuant to incentive share award plan
1,347
(1,347)
—
—
—
Issued pursuant to "At the Market" Agreement
6,228
—
—
—
6,228
Share issue costs
(235)
—
—
—
(235)
Share-based compensation expense
—
1,208
—
—
1,208
As at March 31, 2025
$ 445,533
$ 44,403
$ 958
$ (484,400)
$ 6,494
ONCOLYTICS BIOTECH INC.
CONDENSED INTERIM CONSOLIDATED STATEMENTS OF CASH FLOWS
(unaudited)
(in thousands of Canadian dollars)
Three Months Ended March 31,
2025
2024
Operating Activities
Net loss for the period
$ (6,687)
$ (6,894)
Depreciation - property and equipment
26
28
Depreciation - right-of-use-assets
71
95
Share-based compensation expense
1,208
576
Interest expense on lease liabilities
39
15
Unrealized foreign exchange gain
(61)
(387)
Change in fair value of warrant derivative
(240)
(869)
Net change in non-cash working capital
(854)
(33)
Cash used in operating activities
(6,498)
(7,469)
Investing Activities
Acquisition of property and equipment
—
(46)
Cash used in investing activities
—
(46)
Financing Activities
Proceeds from "At the Market" equity distribution agreement, net
5,993
1,598
Payment of lease liabilities
(103)
(103)
Cash provided by financing activities
5,890
1,495
Decrease in cash and cash equivalents
(608)
(6,020)
Cash and cash equivalents, beginning of period
15,942
34,912
Impact of foreign exchange on cash and cash equivalents
(31)
711
Cash and cash equivalents, end of period
$ 15,303
$ 29,603
About Oncolytics Biotech Inc.
Oncolytics is a clinical-stage biotechnology company developing pelareorep, an intravenously delivered immunotherapeutic agent. Pelareorep has demonstrated promising results in two randomized Phase 2 studies in metastatic breast cancer and Phase 1 and 2 studies in pancreatic cancer. It acts by inducing anti-cancer immune responses and promotes an inflamed tumor phenotype -- turning "cold" tumors "hot" -- through innate and adaptive immune responses to treat a variety of cancers.
Pelareorep has demonstrated synergies with multiple approved oncology treatments. Oncolytics is currently conducting and planning combination clinical trials with pelareorep in solid malignancies as it advances towards registrational studies in metastatic breast cancer and pancreatic cancer, both of which have received Fast Track designation from the FDA. For further information, please visit: www.oncolyticsbiotech.com or follow the company on social media on LinkedIn and on X @ oncolytics.
This press release contains forward-looking statements, within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended and forward-looking information under applicable Canadian securities laws (such forward-looking statements and forward-looking information are collectively referred to herein as "forward-looking statements"). Forward-looking statements contained in this press release include statements regarding Oncolytics' belief as to the potential, mechanism of action and benefits of pelareorep as a cancer therapeutic; our upcoming milestones, including pancreatic cancer translational data from Cohort 1 of the GOBLET study and initial efficacy results from Cohort 5 of the GOBLET study; and other statements related to anticipated developments in Oncolytics' business and technologies. In any forward-looking statement in which Oncolytics expresses an expectation or belief as to future results, such expectations or beliefs are expressed in good faith and are believed to have a reasonable basis, but there can be no assurance that the statement or expectation or belief will be achieved. Such forward-looking statements involve known and unknown risks and uncertainties, which could cause Oncolytics' actual results to differ materially from those in the forward-looking statements. Such risks and uncertainties include, among others, the availability of funds and resources to pursue research and development projects, the efficacy of pelareorep as a cancer treatment, the success and timely completion of clinical studies and trials, Oncolytics' ability to successfully commercialize pelareorep, uncertainties related to the research and development of pharmaceuticals, uncertainties related to the regulatory process and general changes to the economic environment. We may incur expenses or delays relating to events outside of our control, which could have a material adverse impact on our business, operating results and financial condition. Investors should consult Oncolytics' quarterly and annual filings with the Canadian and U.S. securities commissions for additional information on risks and uncertainties relating to the forward-looking statements. Investors are cautioned against placing undue reliance on forward-looking statements. Oncolytics does not undertake any obligation to update these forward-looking statements, except as required by applicable laws.
Company Contact
Jon Patton
Director of IR & Communication
[email protected]
Investor Relations for Oncolytics
Mike Moyer
LifeSci Advisors
+1-617-308-4306
[email protected]
Media Contact for Oncolytics
Michael Rubenstein
LifeSci Communications
[email protected]
Logo - https://mma.prnewswire.com/media/2687646/Oncolytics_Biotech_Inc_Logo.jpg
SOURCE Oncolytics Biotech® Inc.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Cision Canada
an hour ago
- Cision Canada
CUPW Presents New Global Offers to Canada Post
OTTAWA, ON, Aug. 20, 2025 /CNW/ - Today, negotiators for the Canadian Union of Postal Workers (CUPW) returned to the bargaining table with Canada Post to present global offers for both postal bargaining units. With the help of Federal mediators, further talks are scheduled for Friday, August 22, and Monday, August 25. CUPW's latest offers come after postal workers decisively rejected Canada Post's "best and final offers" in a government-forced vote in July. "The Union remains committed to reaching negotiated settlements at the bargaining table," says Jan Simpson, CUPW National President. "CUPW's global offers provide Canada Post practical and workable solutions to expand its services and grow its revenues, while also ensuring postal workers' contributions to an important part of Canada's national infrastructure are valued." Key elements of our latest offer include: Wage increases to make up for the cost-of-living crisis; Targeted increases in the number of corporate vehicles for Rural and Suburban Mail Carriers. No worker should have to risk their safety or pay out of pocket just to do their job; Staffing changes in postal facilities to lessen Canada Post's overreliance on temporary workers who don't have stable schedules or benefits; Scheduling changes to ensure letter carriers can have a work life balance without overburdening; and We are putting forward proposals for CPC to expand services and grow the business, making the corporation stronger and more sustainable for the future. "As CUPE flight attendants have made so visibly clear, the best deals are reached at the table," adds Simpson. "CUPW is focused on ensuring good, stable jobs for all postal workers and strengthening the public post office."
Cision Canada
3 hours ago
- Cision Canada
Investing across Quebec to build safe and strong communities Français
MONTREAL, /CNW/ - The Government of Canada is delivering over $557.5 million to Quebec this year through the Canada Community-Building Fund (CCBF). This allocation is part of the previously announced $2.8 billion in CCBF funding Quebec will receive by 2029 to build communities with stronger and more resilient infrastructure. In addition to its other significant infrastructure investments, the Government of Quebec is contributing more than $1.7 billion by 2029 to projects funded by the CCBF. Investing in basic infrastructure projects – such as public transit, water and wastewater infrastructure, and local roads and bridges – enables communities to grow and build more housing. Today's announcement reflects exactly what Canada's new government has committed to achieving with the Canada Community-Building Fund program, in collaboration with the Government of Quebec. With the funding announced today, communities can build essential and recreational infrastructure so families in Quebec can thrive. The administrative agreement on the CCBF between the Government of Canada and the Government of Quebec provides the flexibility needed to respond strategically to the current and future infrastructure needs of Quebec municipalities. The overall budget, which will allow for investments of more than $4.5 billion by the 2028-2029 fiscal year, is administered by the Société de financement des infrastructures locales (SOFIL)and the funds are distributed to municipalities for projects developed in collaboration with the ministère des Affaires municipales et de l'Habitation and the ministère des Transports et de la Mobilité durable. Quotes "Building a strong Canada starts with building strong communities. We are investing in new infrastructure projects that support housing and foster connected communities. Our investment in Quebec reinforces our commitment to building bold, building strong, and building together in all communities." The Honourable Gregor Robertson, Minister of Housing and Infrastructure "Our government is proud to support Quebec's cities and municipalities in modernizing their essential infrastructure. Whether it's safer roads, more reliable water systems, or accessible recreational spaces, today's investment gives Quebec the means to build a more sustainable and inclusive future for its communities. By supporting local priorities, we are committed to building a stronger Canada." The Honorable Steven Guilbeault, Minister of Canadian Identity and Culture, Minister responsible for Official Languages, and Quebec Lieutenant "The amounts announced today are significant and will enable Quebec municipalities to develop infrastructure that meets the needs of citizens. This agreement guarantees stable funding for the next 10 years for the benefit of all Quebecers." Eric Girard, Minister of Finance and Minister Responsible for Relations with English-Speaking Quebecers "Infrastructure needs are great in all regions of Quebec, and this funding will enable us to work with municipalities to develop a variety of essential projects that directly address local priorities. By joining forces, we are doing much more than investing in our infrastructure: we are investing in the quality of life and vitality of our communities." Andrée Laforest, Minister of Municipal Affairs and Minister Responsible for the Saguenay–Lac-Saint-Jean Region Quick facts The Canada Community-Building Fund (CCBF) will deliver $26.7 billion between 2024-2034 in federal funding to catalyse core infrastructure investments. In 2025-26, the CCBF will provide $2.5 billion to 3,700 communities across Canada to support local infrastructure priorities. In 2025-26, Quebec will receive $557.5 million to make strategic infrastructure investments across 19 project categories. Since 2015, the federal government has invested $26.6 billion across Canada through CCBF, including more than $6.03 billion in Quebec communities. In Quebec, the SOFIL administers programs that provide access to CCBF funding through various programs. The CCBF is a permanent, indexed source of funding provided to provinces and territories, who in turn flow this funding to local governments and other entities to support local infrastructure priorities. Associated Links Follow us on X, Facebook, Instagram and LinkedIn Web: Housing, Infrastructure and Communities Canada SOURCE Department of Housing, Infrastructure and Communities
Cision Canada
3 hours ago
- Cision Canada
Info-Tech LIVE IT Conference for the APAC Region Returns to Brisbane, Australia, March 2026
Info-Tech Research Group, a global research and advisory firm, has announced the return of its premier IT conference, Info-Tech LIVE, to Brisbane, Australia, on March 17-18, 2026. Following a highly successful debut in 2025, the event's second annual APAC edition will once again deliver exclusive insights, high-value networking opportunities, and direct engagement with industry-leading analysts and experts, all under the guiding theme, "Transform IT. Transform Everything." TORONTO, Aug. 20, 2025 /CNW/ - Info-Tech Research Group, a global leader in IT research and advisory, has confirmed that its flagship global IT conference, Info-Tech LIVE, will return to Brisbane March 17-18, 2026, for the second consecutive year. Hosted at the iconic W Brisbane, the two-day event will continue to serve as the APAC region's go-to destination for CIOs, senior IT executives, and technology leaders seeking actionable strategies to navigate the exponentially evolving technology landscape. Building on the momentum of the inaugural 2025 event, which brought together hundreds of CIOs and IT professionals from across Australia, New Zealand, and the wider Asia-Pacific, Info-Tech LIVE 2026 in Brisbane will feature a tactical, hands-on agenda designed by experienced industry experts and practitioners. Attendees will gain practical tools and strategies to address real-world challenges, improve IT-business alignment, and prepare their organizations to capitalize on emerging opportunities. "The success of our first Brisbane event showed just how valuable a region-specific forum can be for technology leaders in the Asia-Pacific," says George Khreish, managing partner at Info-Tech Research Group, APAC."Our return in 2026 is about building on that momentum and providing an even stronger support platform for CIOs and IT leaders in the region to collaborate, gain new perspectives, and leave with practical strategies to drive meaningful change in their organizations." As one of Australia's fastest-growing technology hubs, Brisbane offers a dynamic environment for innovation, making it an ideal location for fostering collaboration and advancing strategic IT priorities in the APAC region. "Info-Tech LIVE in Brisbane has already established itself as a cornerstone event for technology leaders in the region," says Vice President Byron Rudenno of Info-Tech Research Group, APAC. "It's an opportunity to bring the world's best research and global insights directly to our local market, while creating a space for Australian and Asia-Pacific IT leaders to tackle shared challenges with international best practices, exchange ideas, and prepare to lead in an era of exponential technological change reshaping industries." With a continued focus on the theme "Transform IT. Transform Everything," Info-Tech LIVE 2026 in Brisbane will examine the role of IT as the driver of enterprise-wide innovation. Key sessions will cover how exponential technologies can disrupt entire industries and how IT leaders can translate these shifts into tangible business results. The agenda will feature mainstage keynotes, interactive breakouts, lightning rounds on emerging opportunities in the space, and the event's popular one-on-one analyst meetings tailored to attendees' unique priorities. For more information about the event, please visit Info-Tech's LIVE media kit page. Further details on the agenda, keynote speakers, and registration will be announced in the coming months. Follow Info-Tech Research Group on LinkedIn and X for updates. Media Passes for Info-Tech LIVE in Brisbane, March 17-18, 2026 Media professionals, including journalists, podcasters, and influencers, are invited to attend Info-Tech LIVE 2026 in Brisbane to gain exclusive access to research, content, and interviews with industry leaders for their audiences. Media professionals can apply for complimentary in-person passes by contacting [email protected]. About Info-Tech Research Group Info-Tech Research Group is one of the world's leading research and advisory firms, proudly serving over 30,000 IT and HR professionals. The company produces unbiased, highly relevant research and provides advisory services to help leaders make strategic, timely, and well-informed decisions. For nearly 30 years, Info-Tech has partnered closely with teams to provide them with everything they need, from actionable tools to analyst guidance, ensuring they deliver measurable results for their organizations. To learn more about Info-Tech's divisions, visit McLean & Company for HR research and advisory services and SoftwareReviews for software-buying insights. Media professionals can register for unrestricted access to research across IT, HR, and software, and hundreds of industry analysts through the firm's Media Insiders program. To gain access, contact [email protected].
